PARP inhibitor with chemo and HIPEC for ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests if adding a drug called a PARP inhibitor (which helps block cancer cells from repairing themselves) to standard chemotherapy and heated chemotherapy during surgery (HIPEC) can work better together for ovarian cancer that has already been treated with initial chemo. It is for people with a specific type of advanced ovarian cancer who are planning surgery after chemo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage III or stage IV high-grade serous ovarian, fallopian tube, or primary peritoneal cancer (for stage IV, only certain spread patterns are allowed).
- You have already received at least 3 rounds of chemotherapy (carboplatin/paclitaxel) and your cancer has responded or stayed stable.
- You are scheduled for a surgery that removes as much cancer as possible (interval cytoreductive surgery) combined with heated chemotherapy (HIPEC).
- You are generally healthy enough for major surgery (WHO performance status 0-2) and have adequate blood counts, liver, and kidney function.
- You do not have a history of another cancer treated with chemotherapy, and you are not trying to preserve fertility (fertility-sparing surgery).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a second surgery to remove tumors, followed by heated chemotherapy in the abdomen, helps people with ovarian, fallopian tube, or peritoneal cancer whose cancer has returned while taking PARP inhibitor drugs.
This trial tests whether olaparib (a pill cancer medicine) works better than standard platinum chemotherapy after a second surgery for recurrent ovarian cancer. It’s for people whose cancer returned after initial PARP-inhibitor (PARPi) maintenance and aims to see if treatment can control the cancer for longer with acceptable side effects.
This trial tests whether adding a drug that blocks blood vessel growth (angiogenesis inhibitor) to a PARP inhibitor works better than the PARP inhibitor alone for ovarian, fallopian-tube, or peritoneal cancers that have a specific DNA repair problem called HRD. It aims to find a more effective treatment for people with these cancers.
This trial studies whether adding a special heated chemotherapy treatment during surgery (called HIPEC) improves outcomes for some people with ovarian, fallopian tube, or primary peritoneal cancer. It compares surgery alone versus surgery plus HIPEC after you’ve had chemotherapy first.
This trial tests whether adding niraparib (a pill treatment that targets cancer cell DNA repair) after surgery can help people with ovarian cancer that has come back. It focuses on “platinum-sensitive” cases and tries to remove all visible tumor when possible.
This trial compares two drug combinations (fluzoparib plus bevacizumab versus olaparib plus bevacizumab) given after initial chemotherapy to keep advanced ovarian cancer from coming back. Participants must have a specific genetic marker (HRD-positive) and have responded well to their first treatment.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.